Stemcell United Ltd. AI Stock Analysis
Want to see AU:OSS full AI Analyst Report?
Stemcell United Ltd. (OSS) AI Stock Analysis
Stemcell United Ltd.
(ASX:OSS)
The score is primarily constrained by weak financial performance—negative gross profit, ongoing losses, negative equity, and continued cash burn—despite a rebound in revenue. Technical indicators also lean bearish (below DMA20 with negative MACD), while valuation is inconclusive due to a negative P/E and no dividend yield data.
Stemcell United Ltd. (OSS) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 3.13M
- Dividend Yield
- ―
- Average Volume (3M)
- 528.43K
- Price to Earnings (P/E)
- -3.2
- Beta (1Y)
- -0.65
- Revenue Growth
- 877.51%
- EPS Growth
- 67.42%
- Country
- Australia
- Employees
- 31
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Stemcell United Ltd. Business Overview & Revenue Model
Company Description
Ocean Sciences Ltd. is a plant-based biotechnology company, which engages in the business of sourcing, producing, marketing, and selling traditional medicines. The company was founded by Ian Douglas Christiansen on July 25, 1984 and is headquartered...
Stemcell United Ltd. Financial Statement Overview
Summary
Despite a sharp revenue rebound in FY2026 (~A$3.44M vs ~A$0.35M in FY2025), overall financial quality remains weak: negative gross profit, persistent operating losses (net margin ~-52%), negative shareholders’ equity across FY2024–FY2026, and continued cash burn (FY2026 operating/free cash flow about -A$2.14M). These factors indicate ongoing funding dependence and elevated financial risk.
Income Statement
18Very NegativeBalance Sheet
22NegativeCash Flow
15Very Negative| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.44M | 3.44M | 352.38K | 109.97K | 339 | 14.35M |
| Gross Profit | -890.49K | -890.49K | -678.01K | 18.27K | 339 | 2.29M |
| EBITDA | -1.76M | -1.76M | -1.45M | -1.76M | -3.52M | -2.49M |
| Net Income | -1.79M | -1.79M | -1.49M | -2.27M | -4.32M | -3.54M |
Balance Sheet | ||||||
| Total Assets | 1.38M | 1.38M | 541.00K | 691.84K | 2.10M | 7.16M |
| Cash, Cash Equivalents and Short-Term Investments | 259.88K | 259.88K | 152.74K | 134.82K | 1.14M | 685.56K |
| Total Debt | 555.74K | 555.74K | 0 | 508.64K | 0 | 1.30M |
| Total Liabilities | 2.26M | 2.26M | 2.01M | 1.97M | 1.19M | 2.44M |
| Stockholders Equity | -868.82K | -868.82K | -1.45M | -966.82K | 530.13K | 3.20M |
Cash Flow | ||||||
| Free Cash Flow | -2.14M | -2.14M | -932.18K | -1.26M | -1.49M | -4.93M |
| Operating Cash Flow | -2.14M | -2.14M | -929.81K | 0 | 0 | 0 |
| Investing Cash Flow | -8,382 | -8,382 | -2,366 | 185.33K | 6,291 | -914.21K |
| Financing Cash Flow | 2.44M | 2.44M | 962.99K | 697.04K | 1.38M | 281.27K |
Stemcell United Ltd. Peers Comparison
Overall Rating
AU:MSB70Outperform
AU:OCC44Neutral
AU:CYP43Neutral
AU:OSS42Neutral
AU:1AI40Underperform
AU:CMB39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 70Outperform | AUD 2.29B | -26.11 | -10.06% | ― | 555.67% | 49.08% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | AUD 155.26M | -10.47 | -36.83% | ― | 51.07% | -47.63% | |
| 43Neutral | AUD 4.35M | -0.33 | -617.89% | ― | ― | 13.67% | |
| 42Neutral | AUD 3.13M | -3.17 | 216.63% | ― | 877.51% | 67.42% | |
| 40Underperform | AUD 18.25M | -5.14 | -132.20% | ― | ― | -200.00% | |
| 39Underperform | AUD 10.30M | -1.39 | -247.44% | ― | -4.24% | 33.39% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:OSS | Stemcell United Ltd. | 0.01 | -0.01 | -45.00% | |
| AU:CYP | Cynata Therapeutics Limited | 0.01 | -0.23 | -94.56% | |
| AU:1AI | Living Cell Technologies Ltd. | 0.01 | -0.00 | -16.67% | |
| AU:MSB | Mesoblast Limited | 1.76 | -0.54 | -23.48% | |
| AU:OCC | Orthocell Ltd | 0.57 | -0.50 | -46.73% | |
| AU:CMB | Regeneus Ltd. | 0.35 | -0.16 | -31.37% |
Stemcell United Ltd. Corporate Events
Matthew Leonard Ceases as Substantial Holder of Ocean Sciences
Ocean Sciences Ltd is the company named in the filing; the text does not provide information about its industry, products or market focus.The filing records Matthew Leonard’s cessation as a substantial holder on 11 November 2026 and identifies diluti...
Ocean Sciences Announces Issue of 48,981,817 Ordinary Shares
Ocean Sciences Ltd (ASX: OSS) announced the issue of 48,981,817 ordinary shares on 11 November 2026. The company said its notice under section 708A(5) means sales of those securities will fall within the exemption from disclosure restrictions under t...
Ocean Sciences Proposes Issue of 10.5 Million Options
Ocean Sciences Ltd. announced a proposed placement of 10.5 million options, with an exercise price of $0.03 and expiry three years from issue. The proposed securities issue is scheduled for 24 December 2026 and represents a planned capital-markets tr...
Ocean Sciences Proposes Placement of Shares and Options
Ocean Sciences Ltd (ASX: OSS) is identified as the issuer, but the release provides no information about its industry, primary products, services or market focus.The company announced a proposed placement comprising up to 63,636,364 fully paid ordina...
Ocean Sciences secures $700,000 placement for seaweed expansion
Ocean Sciences Ltd, a commercial seaweed supply, research and development company, has secured firm commitments for a $700,000 placement at $0.011 per share. Investors will receive one attaching option per share, exercisable at $0.03 for three years,...
Ocean Sciences launches direct seaweed exports to China and secures Takalar lease extension
Ocean Sciences Ltd reported a pivotal September quarter, highlighted by the start of direct raw seaweed exports to China via its Indonesian subsidiary after securing regulatory approval under the Indonesia–China Mutual Recognition Arrangement. The co...
Ocean Sciences Advances Seaweed Bio-Fertiliser R&D and Maps Commercial Pathways
Ocean Sciences Ltd is advancing its seaweed-based bio-fertiliser program with Temasek Polytechnic, moving from earlier formulation work to validating and optimising extraction protocols from red, green and brown seaweeds. The current phase aims to de...
Ocean Sciences makes first Spinosum seaweed sale to China, broadening carrageenan reach
Ocean Sciences has secured its first commercial sale of Eucheuma spinosum seaweed to China, marking a strategic expansion beyond its traditional focus on Kappaphycus alvarezii, or Cottonii. The 25-metric-tonne shipment to existing customer Greenwich...
Ocean Sciences Signs MOU to Build Indonesia–Australia Seaweed Value Chain
Ocean Sciences Ltd has signed a non-binding Memorandum of Understanding with the Australia-Indonesia Centre to develop an Indonesia–Australia seaweed value chain partnership. The collaboration initially targets value-added seaweed products processed...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
